(0.08%) 5 473.43 points
(0.10%) 39 153 points
(0.39%) 17 786 points
(-0.21%) $80.66
(-3.66%) $2.66
(-0.76%) $2 313.10
(0.21%) $28.93
(3.54%) $1 021.30
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation...
Stats | |
---|---|
今日成交量 | 31 261 |
平均成交量 | 170 264 |
市值 | 88.16M |
EPS | $-0.690 ( Q1 | 2024-05-15 ) |
下一个收益日期 | ( $-0.750 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.750 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0160 (0.69%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-24 | Romano Kelly A | Buy | 27 400 | Common Stock |
2024-06-21 | Romano Kelly A | Buy | 15 000 | Common Stock |
2024-05-24 | Romano Kelly A | Buy | 20 900 | Stock Option (Right to Buy) |
2024-05-24 | Edelman Joseph | Buy | 20 900 | Stock Option (Right to Buy) |
2024-05-24 | Johnson James A | Buy | 20 900 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.77 |
Last 99 transactions |
Buy: 6 729 407 | Sell: 65 252 |
音量 相关性
Athira Pharma, Inc. 相关性 - 货币/商品
Athira Pharma, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-969 000 (0.00 %) |
EPS: | $-3.09 |
FY | 2023 |
营收: | $0 |
毛利润: | $-969 000 (0.00 %) |
EPS: | $-3.09 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.05M (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-4.58 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。